LENZ Therapeutics (LENZ) Insider Guerard Buys 22,100 Shares
Frederic Guerard acquired 22,100 shares of LENZ on June 15, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Frederic Guerard bought 22,100 shares of LENZ Therapeutics, Inc. ($LENZ) on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $LENZ is down 12.2% after 1 week, down 24.7% after 1 month and down 50.7% to date (from the $6.63 close on Jun 15, 2026).
LENZ
LENZ Therapeutics, Inc.
Key Points
- Frederic Guerard bought 22,100 shares of LENZ on June 15, 2026, reflecting insider confidence.
- LENZ shares currently trade at $6.77, with recent analyst targets ranging from $12 to $50.
- Other funds like Versant Venture Management and BlackRock have also adjusted their LENZ holdings recently.
Get $LENZ trade alerts by text
We text you when insiders, Congress or big funds trade $LENZ. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated LENZ Therapeutics, Inc. alert may contain errors. Disclosures
Frederic Guerard, an insider at LENZ, made a notable stock purchase on June 15, 2026. Guerard bought 22,100 shares, contributing to a series of insider transactions that day. This move suggests a vote of confidence in the company's prospects.
Other Institutional Activity in LENZ
Versant Venture Management, LLC significantly boosted its holdings in LENZ, adding 2,656,888 shares to reach a total of 5,313,776 shares worth about $48.6 million. BlackRock, Inc. also increased its position by 284,817 shares, ending with 1,976,823 shares valued at approximately $18.1 million. Meanwhile, FMR LLC trimmed its stake by 104,934 shares, now holding 3,597,784 shares valued at $32.9 million.
LENZ Therapeutics, Inc. Stock Up 66.3%
Shares of LENZ are trading at $6.77. Analyst opinions vary, with Citigroup and HC Wainwright & Co. maintaining a 'buy' rating, setting price targets at $20 and $38 respectively. Piper Sandler recently downgraded the stock to a 'hold' with a $12 target. The stock's performance will be closely watched given these mixed signals.
Insider Buying and Selling at LENZ Therapeutics, Inc.
On June 15, 2026, several insiders, including Frederic Guerard, Zachary Scheiner, and Shelley Thunen, each acquired 22,100 shares of LENZ. None of these transactions were planned under Rule 10b5-1, indicating personal decisions to invest in the company.
Analysts Set New Price Targets
On May 13, 2026, Citigroup maintained its 'buy' rating on LENZ with a price target of $20. HC Wainwright & Co. also upheld its 'buy' rating with a higher target of $38 on May 12, 2026. Conversely, Piper Sandler downgraded LENZ to 'hold' on the same day, setting a $12 target. The average target price from analysts is $30, based on several opinions.
Bottom Line
Insider buying activity at LENZ, including the purchase by Frederic Guerard, often signals potential positive sentiment from those closest to the company. With a current trading price of $6.77 and varied analyst targets, LENZ remains an interesting stock to watch. Keep in mind that insider trades are disclosed after the fact and may not reflect current positions.
Related Filing Alerts
Source: Frederic Guerard's Form 4 filing on $LENZ (Jun 15, 2026). Find the original filing: LENZ Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts